The FDA has started a priority review of Insmed's brensocatib, which is pitching to become the first approved therapy for ...

The FDA has granted priority review to brensocatib to treat patients with non-cystic fibrosis bronchiectasis, according to a ...

The FDA accepts and grants priority review to INSM's NDA for brensocatib to treat patients with non-cystic fibrosis bronchiectasis. A decision is due on Aug. 12, 2025.

Patients with bronchiectasis in China have a high disease burden and a low rate of use of evidence-based treatments.

Millions are affected by lung conditions, often unaware of risks. Asthma + Lung UK's Andy Whittamore shares tips for ...

Insmed's promising drug pipeline includes Brensocatib and Arikayce. See why INSM stock is a strong pick with multi-billion ...

The Bridgewater, N.J., biopharmaceutical company said brensocatib has the potential to become the first and only approved treatment for non-cystic fibrosis bronchiectasis, which causes the lungs' ...

In a report released today, Roy Buchanan from JMP Securities maintained a Buy rating on AN2 Therapeutics, Inc. (ANTX – Research Report), with a ...

The Bridgewater, N.J., biopharmaceutical company said brensocatib has the potential to become the first and only approved treatment for non-cystic fibrosis bronchiectasis, which causes the lungs ...

In a significant recognition of her remarkable contributions to the field of paediatric lung health, Professor Refiloe ...

Consultant Dr Kulkarni carried out a range of tests, which, over the following months, revealed Harmony had tracheomalacia ...